Kaposi's Sarcoma Clinical Trial
Official title:
Phase II Trial for the Treatment of Advanced Classical Kaposi's Sarcoma With the HIV Protease Inhibitor Indinavir in Combination With Chemotherapy
The purpose of this study is to determine the clinical response to daily Indinavir oral administration in association with a conventional chemotherapy based on cycles of systemic Vinblastine +/- Bleomycin in patients affected by advanced classical (non HIV-associated) Kaposi's sarcoma
It has been recently demonstrated that HIV protease inhibitors (HIV-PI) exert direct anti-angiogenic and anti-tumor actions by blocking endothelial and tumor cell invasion and matrix metalloprotease (MMP) activity. Based on this data, we have started a phase II trial for the treatment of HIV-negative patients with CKS with the HIV-PI Indinavir. Indinavir was well tolerated and induced KS regression/improvement in early-stage disease, and prolonged stabilization in late-stage KS. Response required high plasma drug concentrations indicating a "therapeutic" drug threshold, and was associated with a decrease of circulating endothelial cells (CEC), basic fibroblast growth factor and MMP2 plasma levels. However, large, confluent tumor masses were generally not responsive (Monini et al, AIDS 2009). Thus, advanced KS may benefit at best by treatment with IND upon tumor debulking by conventional chemotherapy. ;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02201420 -
Evaluation of Technetium Tc 99m Tilmanocept (Lymphoseek®) Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT and SPECT/CT Imaging
|
Phase 2 | |
Terminated |
NCT00686842 -
PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
|
Phase 1/Phase 2 | |
Completed |
NCT00339326 -
Risk Factors for Non-HIV-Related Kaposi s Sarcoma
|
||
Completed |
NCT01352117 -
Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
|
Phase 3 | |
Completed |
NCT01276236 -
Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)
|
Phase 2 | |
Completed |
NCT00001535 -
Twins Study of Gene Therapy for HIV Infection
|
Phase 1 | |
Completed |
NCT00540566 -
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
|
||
Completed |
NCT00380770 -
HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT
|
Phase 4 | |
Completed |
NCT00001294 -
Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens
|
N/A | |
Completed |
NCT00055237 -
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
|
Phase 2 | |
Completed |
NCT00026728 -
Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States
|
N/A | |
Terminated |
NCT00287495 -
BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma
|
Phase 1 | |
Completed |
NCT00581815 -
Spectroscopy With Surface Coils and Decoupling
|
Phase 1 | |
Recruiting |
NCT00006518 -
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
|
||
Completed |
NCT00001560 -
Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers
|
N/A | |
Completed |
NCT00982449 -
124I-FIAU Imaging in EBV and KSHV Associated Cancers
|
N/A | |
Recruiting |
NCT03300830 -
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
|
||
Completed |
NCT00006171 -
Effects of Potent Antiretroviral Therapy on Kaposi s Sarcoma
|
||
Completed |
NCT02029430 -
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
|
Phase 2 | |
Completed |
NCT00026793 -
Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions
|